01—Abstract
Summary
Summary of the 8-K filed October 28, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported record third-quarter 2026 results, with net sales of $951.7 milliona, up 8% on both a reported and organic basis versus the prior year period.
Reported diluted EPS attributable to IDEX was $1.95b, up from $1.70, and record adjusted diluted EPS was $2.33, up from $2.03, with both reported and adjusted EPS increasing 15%. Orders were $991.2 million, up 13% on both a reported and organic basis. Gross margin rose to 45.1% from 44.5%, and Adjusted EBITDA margin rose to 27.8% from 27.3%.
The Health & Science Technologies segment drove much of the growth, with net sales up 14% and organic sales up 13%, supported by AI-driven demand for data center power and semiconductor markets, as well as space and defense. Cash flow was strong, with operating cash flow of $239.5 millionc and free cash flow of $214.3 million, compared with $188.7 million a year earlier. The company returned $129 million to shareholders through dividends and share repurchases during the quarter, and it amended and restated its $800 million revolving credit facility to extend maturity to September 2031.
Management raised full-year 2026 guidance, now projecting organic sales growth of 6.5% to 6.8%, up from 5% to 6%, and adjusted diluted EPS of $8.91 to $8.96d, up from $8.70 to $8.85. The filing furnishes the earnings press release as Exhibit 99.1 under Item 2.02, and that information is not deemed filed for Section 18 purposes.
02—Key points
Key Highlights
- Record third-quarter net sales of $951.7 million, up 8% on both a reported and organic basis
- Reported diluted EPS of $1.95 and record adjusted diluted EPS of $2.33, both up 15%
- Orders of $991.2 million, up 13% on both a reported and organic basis
- Health & Science Technologies segment net sales rose 14%, with organic growth of 13% driven by AI-related data center power and semiconductor demand
- Full-year 2026 guidance raised: organic sales growth of 6.5% to 6.8% and adjusted diluted EPS of $8.91 to $8.96
- Operating cash flow of $239.5 million and free cash flow of $214.3 million in the quarter, both higher than the prior year
- Returned $129 million to shareholders via dividends and share repurchases; revolving credit facility amended and extended to September 2031
03—Questions
Frequently Asked Questions
How did IDEX perform in the third quarter of 2026?
Net sales were a record $951.7 million, up 8% reported and organically. Gross margin increased to 45.1% from 44.5%, and Adjusted EBITDA margin increased to 27.8% from 27.3%. Net income attributable to IDEX was $144.1 million, compared with $127.8 million in the prior year period.
What drove the growth in the quarter?
The filing attributes the organic sales increase to higher volumes, primarily in the Health & Science Technologies segment, and positive price across the segments. Management cites AI-driven demand for data center power and semiconductor markets, along with strength in space and defense.
Did IDEX change its full-year outlook?
Yes. Full-year organic sales growth is now projected at 6.5% to 6.8%, up from 5% to 6%. Full-year adjusted diluted EPS is now expected to be $8.91 to $8.96, up from $8.70 to $8.85. The company notes that it does not reconcile these forward-looking non-GAAP measures to U.S. GAAP because certain items cannot be reasonably estimated without unreasonable effort.
How strong was cash generation and capital return?
Operating cash flow was $239.5 million, versus $203.5 million a year earlier, and free cash flow was $214.3 million, versus $188.7 million. The company returned $129 million to shareholders through dividends and share repurchases during the quarter.
What was the order performance?
Orders were $991.2 million, up 13% on both a reported and organic basis, compared with $880.3 million in the prior year period. Management described booking nearly $1 billion in orders in the quarter.
04—Continue